Alkermes PLC
Slēgts
SektorsVeselības aprūpe
50.18 4.32
Pārskats
Akcijas cenas izmaiņa
24h
Min
47.88
Max
51.57
Ienākumi | -116M -66M |
|---|---|
Pārdošana | 8.4M 393M |
P/E Sektora vidējais | 51.133 50.958 |
EPS | 0.38 |
Peļņas marža | -16.92 |
Darbinieki | 2,050 |
EBITDA | -98M -22M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +4.01% upside |
Nākamie ieņēmumi | 2026. g. 28. jūl. |
|---|
Tirgus kapitalizācija | 2B 7.7B |
|---|---|
Iepriekšējā atvēršanas cena | 45.86 |
Iepriekšējā slēgšanas cena | 50.18 |
Ziņu noskaņojums
By Acuity
10%
90%
13 / 342 Rangs Healthcare
Alkermes PLC Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
